Hepatic inflammatory responses in liver fibrosis

L Hammerich, F Tacke - Nature Reviews Gastroenterology & …, 2023 - nature.com
Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

Cellular and molecular mechanisms underlying liver fibrosis regression

A Caligiuri, A Gentilini, M Pastore, S Gitto, F Marra - Cells, 2021 - mdpi.com
Chronic liver injury of different etiologies may result in hepatic fibrosis, a scar formation
process consisting in altered deposition of extracellular matrix. Progression of fibrosis can …

The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: recent evolution and open questions

P Deltenre, A Zanetto, D Saltini, C Moreno… - Hepatology, 2023 - journals.lww.com
In selected patients with cirrhosis and ascites, transjugular intrahepatic portosystemic shunt
(TIPS) placement improves control of ascites and may reduce mortality. In this review, we …

HCC and molecular targeting therapies: Back to the future

L Rinaldi, E Vetrano, B Rinaldi, R Galiero, A Caturano… - Biomedicines, 2021 - mdpi.com
Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer in the
world. Recently, the effectiveness of new antiviral therapies and the HBV vaccine have …

[HTML][HTML] Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response

C Montaldo, M Terri, V Riccioni, C Battistelli… - Journal of …, 2021 - Elsevier
Background & Aims Patients with HCV who achieve a sustained virological response (SVR)
on direct-acting antiviral (DAA) therapy still need to be monitored for signs of liver disease …

Long-term hepatocellular carcinoma development and predictive ability of non-invasive scoring systems in patients with HCV-related cirrhosis treated with direct …

GP Caviglia, G Troshina, U Santaniello, G Rosati… - Cancers, 2022 - mdpi.com
Simple Summary In the present study we investigated the ability of different non-invasive
scoring systems (ie, Forns index, APRI, FIB-4, ALBI, and aMAP) to predict hepatocellular …

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

HW Yoo, JY Park, SG Kim, YK Jung, SH Lee, MY Kim… - Scientific reports, 2022 - nature.com
We prospectively investigated the changes of liver stiffness (LS) and the occurrence of
hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct …

Impact of eradication of hepatitis C virus on liver-related and-unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR

M Nakagawa, Y Asahina, S Kakinuma… - Journal of …, 2023 - Springer
Hepatitis C virus infection is characterized by chronic liver inflammation and fibrogenesis,
leading to end-stage liver failure and hepatocellular carcinoma over the course of 20 to 30 …

Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis

JH An, DA Park, MJ Ko, SB Ahn, JJ Yoo… - Journal of Personalized …, 2022 - mdpi.com
DAA therapy is known to clear hepatitis C virus infection in patients with decompensated
cirrhosis (DC). However, the safety and benefits of DAA in DC remain unclear, especially …

Current therapy of chronic viral Hepatitis B, C and D

JF Schlaak - Journal of Personalized Medicine, 2023 - mdpi.com
The majority of chronic viral hepatitis cases are induced via infection with the hepatitis B
virus (HBV), hepatitis C virus (HCV), or hepatitis D virus (HDV). These patients are at …